Firstly, Edwards Lifesciences would like to express its gratitude to everyone in the NHS serving the patients of the UK during this challenging time.

In the current context of the treatment and referral for patients with aortic stenosis, Edwards Lifesciences would like to help contribute to the Heart Team Community by facilitating a webinar to address the current guidance, challenges and today's future for TAVI when treating patients with Aortic Stenosis.

20th May 2020

The Management of Aortic Stenosis in Today's Future

Presented by Prof. Simon Redwood (St Thomas‘s Hospital, London), Prof. Nick Curzen (BCIS President, Southampton General Hospital), Prof. Neil Ruparelia (Hammersmith Hospital, London), Prof. Rajesh Kharbanda (Oxford University Hospital), Dr. Sagar Doshi (Queen Elizabeth Hospital, Birmingham) & Dr. Iqbal Malik (Hammersmith Hospital, London).

Prof. Simon Redwood: Welcome and Introduction

Prof. Nick Curzen: Current Situation and Guidance

Prof. Neil Ruparelia: The Management Challenge of Aortic Stenosis in the COVID 19 Crisis

Dr. Sagar Doshi: Re-starting Elective TAVI – Risk Stratification

Prof. Rajesh Kharbanda: The Practicalities of Doing Even One TAVI in the COVID 19 Era

Panel discussion and Q&A

15th July 2020

Pathway Management for Aortic Stenosis Patients in Today’s Future

Presented by Dr. Simon Kennon (St. Bartholomew’s Hospital, London), Prof. Simon Ray (President of BCS and GIRFT Lead), Dr. Paul Williams (James Cook University Hospital, South Tees), Dr. Dougie Muir (James Cook University Hospital, South Tees), Mr. Ranjit Deshpande (Kings College Hospital, London), Prof. Philip MacCarthy (Kings College Hospital, London), Dr. Clare Appleby (Liverpool Heart and Chest Hospital), Prof. Huon Gray (Cardiac Network Clinical Lead, NHS England, London Region) & Prof. Neal Uren (Royal Infirmary of Edinburgh).

Dr. Kennon: Welcome and Introduction

Prof. Ray: Optimised Patient Pathway: A GIRFT Perspective

Dr. Muir & Dr. Williams: Optimised Clinical Pathway: A Single Common Aortic Valve MDT

Prof. MacCarthy & Mr Deshpande: The Heart Team Approach

Dr. Appleby: Minimising Patient Exposure: Efficiencies for the “New Norm”

Prof. Gray: Covid-19: Challenges Delivering Urgent Elective Cardiac Services in London

Prof. Uren: Q&A Session

Dr. Kennon: Summary

Aortic Stenosis is a ticking time bomb and many patients may die while waiting for AVR¹ with 40% of patients on a waiting list requiring an unplanned hospital admission in approximately a four month period².

In the current context of the treatment for patients with aortic stenosis, Edwards Lifesciences would like to help contribute to the Heart Team Community by facilitating a webinar on future considerations for aortic stenosis patients for optimal treatment with minimal hospital footprint.

24th September 2020

The Future of TAVI in the UK

Featuring Prof. Philip MacCarthy (Kings College Hospital, London), Prof. Nick Curzen (BCIS President, Southampton University Hospital), Dr. Dan Blackman (EAPCI Valve For Life UK Lead, Leeds Teaching Hospitals NHS Trust), Prof. Neil Ruparelia (Hammersmith Hospital, London) and Mr. Wil Woan (Heart Valve Voice).

Prof. MacCarthy: Welcome and Introduction

Prof. Curzen: The Future of TAVI in the UK from BCIS

Dr. Blackman: Valve For Life

Panel Discussion and Q&A

  1. Malaisrie, SC, et al. Mortality while waiting for aortic valve replacement. Ann Thorac Surg. 2014
  2. Elbaz-Greener G, et al. Association Between Wait Time for Transcatheter Aortic Valve Replacement and Early Post Procedural Outcomes. J Am Heart Assoc. 2019